11.06.2007 12:00:00

King Pharmaceuticals Joins Together Rx Access(TM) To Help Americans Without Prescription Drug Coverage

King Pharmaceuticals, Inc. (NYSE:KG) announced today that it is the 11th pharmaceutical company to join Together Rx Access,™ a prescription savings program created by leading pharmaceutical companies to help individuals and families gain access to meaningful savings on prescription medicines. "We are extremely pleased to welcome King Pharmaceuticals as a new member company and commend its commitment to helping Americans without prescription drug coverage gain access and savings,” said Roba Whiteley, executive director of Together Rx Access. "The Together Rx Access™ Program continues to gain momentum, enrolling nearly 10,000 Americans each week.” An estimated 47 million Americans, including nine million children, do not have healthcare coverage. The uninsured population includes two-income families, single parents, the self-employed, recent college graduates, and low-wage workers, among others. In fact, eight out of 10 uninsured people are in families where one or more members are employed. "We are proud to participate in the Together Rx Access Program, which offers immediate help to eligible individuals and their families, and has proven it can make a real difference,” said Brian A. Markison, Chairman and CEO of King Pharmaceuticals, Inc. "This program is a great example of our industry recognizing and responding to a public need by coming together to develop and participate in an innovative and effective solution.” "The participation of King Pharmaceuticals enhances the Together Rx Access Program’s value to cardholders by expanding the number of brand-name prescription medicines in the Program, including those to treat many common conditions such as hypertension, hypothyroidism and chronic pain,” added Whiteley. King’s participation in the Together Rx Access Program will provide cardholders with savings on products such as Altace® (ramipril); Skelaxin® (metaxalone); Avinza® (morphine sulfate extended release); Sonata® (zaleplon); and Levoxyl® (levothyroxine sodium tablets, USP). King Pharmaceuticals joins the following companies already participating in the Together Rx Access Program: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen, L.P.; Johnson & Johnson Wound Management, a Division of ETHICON, Inc.; LifeScan, Inc.; McNeil Pediatrics, a Division of McNeil-PPC, Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech Products, L.P.; Ortho-McNeil, Inc.; Ortho-McNeil Neurologics, Inc.; OrthoNeutrogena, a Division of Ortho-McNeil Pharmaceutical, Inc.; Ortho Women’s Health & Urology, a Division of Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc; PriCara, a Unit of Ortho-McNeil, Inc.; sanofi-aventis U.S. LLC.; Takeda Pharmaceuticals North America, Inc.; TAP Pharmaceutical Products Inc.; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P.; and Vistakon Pharmaceuticals, LLC. About King Pharmaceuticals, Inc. King Pharmaceuticals, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management. About Together Rx Access The Together Rx Access Card was created by leading pharmaceutical companies to help hardworking Americans and their families gain access to meaningful savings on prescriptions right at their neighborhood pharmacy. Most cardholders save 25 to 40 percent1 on brand-name prescription products, including medicines to treat high cholesterol, diabetes, asthma, and many other conditions. More than 300 brand-name prescription products2 are included in the Program. Savings are also available on a range of generic products. To qualify for the free Together Rx Access Card, applicants cannot be eligible for Medicare or have public or private prescription drug coverage. To be eligible, household income of less than $30,000 for a single person or $60,000 for a family of four (income eligibility is adjusted for family size) is required. Applicants must be legal residents of the United States or Puerto Rico. It is easy to enroll in the Program and easy to use the Card once enrolled. The Card is accepted at the majority of pharmacies nationwide and in Puerto Rico. Cardholders simply bring the Card to their pharmacist along with their prescription, and the savings are calculated right at the pharmacy counter. There are no enrollment costs, monthly dues or hidden charges. Together Rx Access also directs individuals to the Partnership for Prescription Assistance (PPA), a clearinghouse for more than 475 public and private assistance programs, including 180 offered by pharmaceutical companies. For more information about the Together Rx Access Card and to enroll in the Program, contact Together Rx Access at 1-800-966-0407, or visit TogetherRxAccess.com. Together Rx Access and the Together Rx Access logo are trademarks of Together Rx Access, LLC. All other marks are the property of their respective owners. © 2007 Together Rx Access, LLC. 1 Each card user's savings depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased. Participating companies independently set the level of savings offered and the products included in the program. Those decisions are subject to change. 2 Visit TogetherRxAccess.com for the most current list of brand-name medicines and products.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Pfizer Inc.mehr Analysen

14.11.24 Pfizer Neutral UBS AG
01.11.24 Pfizer Neutral UBS AG
30.10.24 Pfizer Buy Goldman Sachs Group Inc.
29.10.24 Pfizer Buy Jefferies & Company Inc.
24.10.24 Pfizer Neutral JP Morgan Chase & Co.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Pfizer Inc. 24,57 0,74% Pfizer Inc.

Indizes in diesem Artikel

S&P 500 5 998,74 -0,38%